News >

Focus in Oncogene-Driven NSCLC Turns to Sequencing Strategies, Overcoming Resistance

Caroline Seymour
Published: Thursday, Apr 25, 2019

Kartik Konduri, MD

Kartik Konduri, MD
The ability to target driver mutations among patients with non–small cell lung cancer (NSCLC) continues to grow with combination therapies and newer agents, and research is now focusing on sequential treatment for other key targets, explained Kartik Konduri, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication